Harmony Biosciences Holdings Q3 2026 Results: Net Income $48.2M, Down 5.2% YoY
Harmony Biosciences reported net product revenue of $268.9 million for the third quarter of 2026, a 12.3% increase year-over-year. Net income for the nine months ended September 30, 2026, rose to $156.1 million compared to $136.2 million in the prior year, despite higher operating expenses driven by research and development.
- Key figure
- Net income $48.2M · -5.2% YoY